Andrew Place, MD, PhD
Vice President, Chief Medical Officer, Division of Hematology/Oncology Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Image
Andrew Place, MD, PhD
Vice President, Chief Medical Officer, Division of Hematology/Oncology Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Assistant Professor of Pediatrics, Harvard Medical School
Medical Services
Languages
English
Education
Undergraduate School
Swarthmore College
1996
Swarthmore
PA
Graduate School
PhD
Dartmouth Medical School
2004
Hanover
NH
Medical School
Dartmouth Medical School
2006
Hanover
NH
Residency
Boston Combined Residency Program (BCRP)
2009
Boston
MA
Fellowship
Pediatric Hematology-Oncology
Dana-Farber Cancer Institute
2012
Boston
MA
Certifications
American Board of Pediatrics (Hematology-Oncology)
Publications
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia. View Abstract
Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. View Abstract
Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial. View Abstract
Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium. View Abstract
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. View Abstract
Acute Promyelocytic Leukemia With Torque Teno Mini Virus::RARA Fusion: An Approach to Screening and Diagnosis. View Abstract
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. View Abstract
Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. View Abstract
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. View Abstract
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. View Abstract
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium. View Abstract
Use of the osmolal gap in diagnosing mixed physiology hyponatremia in a child with B-cell acute lymphoblastic leukemia. View Abstract
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients. View Abstract
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. View Abstract
Reply to: Comment on: Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. View Abstract
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. View Abstract
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. View Abstract
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. View Abstract
Ocular abnormalities at diagnosis and after the completion of treatment in children and adolescents with newly diagnosed acute lymphoblastic leukemia. View Abstract
B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations. View Abstract
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. View Abstract
Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. View Abstract
Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. View Abstract
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. View Abstract
Corrigendum. View Abstract
Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. View Abstract
Limiting Vancomycin Exposure in Pediatric Oncology Patients With Febrile Neutropenia May Be Associated With Decreased Vancomycin-Resistant Enterococcus Incidence. View Abstract
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. View Abstract
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. View Abstract
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. View Abstract
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. View Abstract
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. View Abstract
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. View Abstract
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. View Abstract
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. View Abstract
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. View Abstract
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. View Abstract
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. View Abstract
Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. View Abstract
Therapeutic approaches to haematological malignancies in adolescents and young adults. View Abstract
Future of clinical genomics in pediatric oncology. View Abstract
The microenvironment in breast cancer progression: biology and implications for treatment. View Abstract
The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. View Abstract
Pre-Clinical Evaluation of the Novel Synthetic Triterpenoid CDDO-Imidazolide View Abstract
The synthetic triterpenoid, CDDO-Imidazolide, activates heme oxygenase-1 and other Nrf2-responsive genes in human leukemia cells
View Abstract
The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. View Abstract
Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. View Abstract
Pre-Clinical Evaluation of Synthetic Triterpenoids for Prevention and Treatment of Cancer View Abstract
A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. View Abstract
Synthetic Triterpenoids Induce Differentiation of Human Leukemia Cells and Reduce Tumor Burden in Murine Cancer Models View Abstract
The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. View Abstract
Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. View Abstract
Bcl-xL blocks activation of related adhesion focal tyrosine kinase/proline-rich tyrosine kinase 2 and stress-activated protein kinase/c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate. View Abstract
A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. View Abstract